Adaptimmune Therapeutics PLC (ADAP)
0.5912
-0.18
(-23.28%)
USD |
NASDAQ |
Nov 14, 16:00
0.60
+0.01
(+1.49%)
After-Hours: 20:00
Adaptimmune Therapeutics Research and Development Expense (Quarterly): 40.45M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 40.45M |
| March 31, 2024 | 35.21M |
| December 31, 2023 | 33.21M |
| September 30, 2023 | 37.79M |
| June 30, 2023 | 29.96M |
| March 31, 2023 | 25.55M |
| December 31, 2022 | 23.05M |
| September 30, 2022 | 33.18M |
| June 30, 2022 | 34.74M |
| March 31, 2022 | 36.75M |
| December 31, 2021 | 29.50M |
| September 30, 2021 | 28.21M |
| June 30, 2021 | 28.87M |
| March 31, 2021 | 24.51M |
| December 31, 2020 | 25.78M |
| September 30, 2020 | 24.07M |
| June 30, 2020 | 20.46M |
| March 31, 2020 | 21.26M |
| December 31, 2019 | 20.35M |
| Date | Value |
|---|---|
| September 30, 2019 | 29.62M |
| June 30, 2019 | 25.51M |
| March 31, 2019 | 22.02M |
| December 31, 2018 | 22.77M |
| September 30, 2018 | 23.48M |
| June 30, 2018 | 26.62M |
| March 31, 2018 | 25.73M |
| December 31, 2017 | 25.15M |
| September 30, 2017 | 24.03M |
| June 30, 2017 | 19.59M |
| March 31, 2017 | 18.62M |
| December 31, 2016 | 16.85M |
| September 30, 2016 | 15.61M |
| June 30, 2016 | 16.86M |
| March 31, 2016 | 14.48M |
| September 30, 2015 | 9.885M |
| December 31, 2014 | 5.005M |
| September 30, 2014 | 3.862M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
20.35M
Minimum
Dec 2019
40.45M
Maximum
Jun 2024
29.10M
Average
28.87M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 10.55M |
| NuCana PLC | 8.540M |
| Autolus Therapeutics PLC | 36.61M |
| Bicycle Therapeutics PLC | 48.26M |